Hims & Hers shifting focus to personalized weight-loss drugs in changing US market

From Yahoo Finance: 2025-06-10 06:14:00

Hims & Hers Health is shifting focus to personalized weight-loss drugs after FDA restrictions on compounded versions of popular drugs. Despite a 14% stock drop post-deadline, Hims is selling customized Wegovy doses starting at $165/month. Analysts question if these offerings truly qualify as personalized and if Novo Nordisk will allow it.

CVS Health and Cigna have announced new strategies regarding weight-loss drug coverage, potentially impacting cash-pay vendors like Hims. Leerink’s Cherny warns that expanded insurance coverage may hinder Hims’ growth targets. The company aims for $6.5 billion in revenue by 2030, with analysts forecasting $2.4 billion by 2025.

Hims CEO Dudum targets under-insured consumers seeking weight-loss drugs due to high insurance deductibles. Plans include offering more personalized products, expanding into the UK and Europe, and partnering with Novo Nordisk’s direct-pay pharmacy. However, plans to continue selling compounded semaglutide may complicate this partnership.

Hims sells compounded semaglutide at a fraction of Wegovy’s price but may face legal challenges from Novo Nordisk. The company projected sales of at least $725 million in the first quarter of 2025. Cigna and CVS have introduced new pricing strategies for weight-loss drugs, potentially impacting Hims’ market.

Read more: Analysis-Hims & Hers says its weight-loss business can grow as US market changes